Bone Density Partially Recovers in Transgender Youth After Puberty Blockers, Study Finds

Bone growth in transgender and gender-diverse adolescents experienced a slowdown compared to their cisgender peers during periods of pubertal suppression. However, a significant partial recovery of bone density was observed after these adolescents discontinued puberty blockers and commenced gender-affirming hormone therapy. This finding emerges from a systematic review and meta-analysis that synthesized data from multiple studies to assess the long-term skeletal health outcomes for this population.

The review, which included data from 13 studies encompassing 318 participants, indicated that while bone mineral accrual was diminished during the use of gonadotropin-releasing hormone (GnRH) analogs, the initiation of cross-sex hormones led to a partial rebound. GnRH analogs, such as leuprolide acetate, are medications used to temporarily halt the progression of puberty by suppressing the production of sex hormones like testosterone and estrogen. This pause is often prescribed to transgender and gender-diverse adolescents to allow them more time to explore their gender identity without the irreversible physical changes of puberty associated with their sex assigned at birth.

Specifically, the analysis revealed that bone mineral density (BMD) at the lumbar spine and total hip showed improvements following the transition to hormone therapy. Lumbar spine BMD refers to the density of bone in the lower back, a common site for osteoporosis-related fractures. Total hip BMD measures the density of bone in the hip joint, another critical area for bone health. The introduction of cross-sex hormones, such as estrogen for transgender women or testosterone for transgender men, aims to induce the development of secondary sex characteristics aligned with their gender identity and also plays a crucial role in bone metabolism. This suggests that while puberty blockers can impact bone development, the subsequent introduction of gender-affirming hormones can mitigate some of these effects and promote bone health recovery.

Researchers highlighted that the period of pubertal suppression, typically involving GnRH analogs, is intended to pause the development of secondary sex characteristics, allowing adolescents more time to explore their gender identity. While this intervention is crucial for many, its potential impact on bone health has been a subject of ongoing investigation. The current meta-analysis provides robust evidence that the skeletal system can respond positively to the introduction of appropriate hormone therapy, underscoring the importance of comprehensive care for transgender youth.

The study's authors emphasized that the observed partial recovery does not necessarily mean a complete return to the bone density levels expected in cisgender peers who have undergone natural puberty. Natural puberty, driven by endogenous sex hormones, is a critical period for peak bone mass acquisition. Therefore, any disruption, even if temporary, could have lasting implications. Further research is recommended to fully understand the long-term skeletal implications and to optimize treatment protocols. The findings are particularly relevant for endocrinologists, pediatricians, and other healthcare providers involved in the care of transgender and gender-diverse adolescents, informing clinical decision-making regarding the timing and type of hormonal interventions and the necessity of ongoing bone health monitoring. This research contributes to the growing body of evidence supporting the safety and efficacy of gender-affirming care.